Pharmaceuticals

Global Thyroid Cancer Drugs Industry Trends and Market Forecast 2026–2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the thyroid cancer drugs market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Thyroid Cancer Drugs Market in 2030?

The thyroid cancer drugs market has experienced substantial expansion in recent years. It is anticipated to increase from $1.32 billion in 2025 to $1.47 billion in 2026, growing at a compound annual growth rate (CAGR) of 11.8%. This historical growth can be attributed to a surge in thyroid cancer incidence, the adoption of kinase inhibitors, improvements in cancer diagnostics, the expansion of oncology hospitals, and greater access to targeted therapies.

The thyroid cancer drugs market size is projected to experience significant growth in the upcoming years, expanding to **$2.39 billion in 2030** at a **compound annual growth rate (CAGR) of 12.8%**. This anticipated growth during the forecast period can be attributed to the rise in personalized oncology drugs, an increasing incidence of advanced thyroid cancer, intensified clinical trial activity, the broader expansion of immunotherapy combinations, and higher oncology healthcare spending. Key trends for the forecast period include the rising adoption of targeted multikinase therapies, an increasing use of combination drug regimens, a growing focus on advanced and refractory thyroid cancer, the expansion of precision oncology treatment approaches, and increased hospital-based thyroid cancer management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp

What Drivers Are Influencing Production Trends In The Thyroid Cancer Drugs Market?

The expansion of the thyroid cancer drugs market is anticipated to be driven by a rising number of thyroid cancer cases. Thyroid cancer involves the development of malignant tumors within the thyroid gland, necessitating prompt diagnosis and effective treatment to prevent its progression and spread. This increase in thyroid cancer can be attributed to a combination of improved detection methods, stemming from more sensitive diagnostic procedures, and elevated exposure to environmental factors. The growing prevalence of thyroid cancer supports the demand for thyroid cancer drugs by boosting the need for various treatments such as targeted therapies, immunotherapies, radiopharmaceuticals, and hormone-suppressing medications, which collectively improve patient outcomes and long-term survival. For instance, in September 2025, Cancer Research United Kingdom, a UK-based non-profit organization focused on cancer research and patient support, projected approximately 6,600 new cases of thyroid cancer annually by 2038-2040. They also indicated that incidence rates are expected to increase by 27% from about 7.3 cases per 100,000 people per year in 2024-2026 to roughly 9.2 cases per 100,000. Thus, the increasing incidences of thyroid cancer are a key factor propelling the growth of the thyroid cancer drugs market.

Which Segment Groups Are Influencing The Thyroid Cancer Drugs Market?

The thyroid cancer drugs market covered in this report is segmented –

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users

Subsegments:

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib

8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab

How Are New Market Trends Shaping The Landscape Of The Thyroid Cancer Drugs Market?

Leading companies in the thyroid cancer market are developing innovative products, such as selpercatinib, to enhance treatment options and patient outcomes. Selpercatinib, marketed as Retevmo, is a medication designed to treat various cancers associated with Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For example, in September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, secured approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health, for treating advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This approval covers both adult and pediatric patients aged 2 years and older who require systemic therapy. The recent traditional approval represents a significant step forward in therapeutic choices for patients suffering from this specific variant of thyroid cancer.

Who Are The Top-Performing Companies In The Thyroid Cancer Drugs Market In Recent Years?

Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Thyroid Cancer Drugs Market?

North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Thyroid Cancer Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2601&type=smp

Browse Through More Reports Similar to the Global Thyroid Cancer Drugs Market 2026, By The Business Research Company

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Anti Thyroid Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report

Breast Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795